Views & Analysis Specialty pharma’s next big opportunity: it’s time for patie... In January 2020, the financial conglomerate Visa
News Novo puts $285m into monthly GLP-1 based on Ascendis tech Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.
